Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days

Curanex Pharmaceuticals Inc

Contributing Author

Recent Articles by Curanex Pharmaceuticals Inc

May-14	Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission CURX GlobeNewswire
Apr-08	Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline CURX GlobeNewswire
Apr-06	Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care CURX +7.94% GlobeNewswire
Apr-02	Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company's Evolution Into a Broader Therapeutics Development Company CURX GlobeNewswire
Mar-30	Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission CURX GlobeNewswire
Mar-18	Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission CURX +10.43% GlobeNewswire
Mar-12	Curanex Expands Scientific Advisory Board With Two Distinguished Researchers CURX -11.59% GlobeNewswire
Mar-11	Curanex Appoints Two Veteran Industry Leaders to Scientific Advisory Board CURX +6.16% GlobeNewswire
Mar-05	Curanex Forms World Class Scientific Advisory Board CURX GlobeNewswire
Feb-25	Curanex Provides Operational Update on Key Regulatory Milestones CURX GlobeNewswire
Oct-22	Curanex Pharmaceuticals Inc. Engages Strategic Investor Relations to Enhance Investor Communications and Engagement CURX +14.39% GlobeNewswire
Sep-12	Curanex Pharmaceuticals Inc. Announces Exercise of the Over-Allotment Option by Underwriters CURX GlobeNewswire
Aug-27	Curanex Pharmaceuticals Inc. Announces Closing of its Initial Public Offering CURX +15.92% CURX +11.37% GlobeNewswire
Aug-26	Curanex Pharmaceuticals Inc. Announces Pricing of its Initial Public Offering CURX GlobeNewswire

Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)